Real-world use of apixaban for stroke prevention in atrial fibrillation: A systematic review and meta-analysis

Stroke

Volumn 49, Issue 1, 2018, Pages 98-106

  Proietti, Marco ^a,b   Romanazzi, Imma ^a   Romiti, Giulio Francesco ^a   Farcomeni, Alessio ^c   Lip, Gregory Y H ^a,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

Apixaban; Atrial fibrillation; Major bleeding; Stroke; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; ORAL BALANCE; POLYMER; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; SALIVA SUBSTITUTE; VITAMIN K GROUP; WARFARIN;

ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPLICATION; FEMALE; HUMAN; MALE; META ANALYSIS; RISK FACTOR;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; POLYMERS; PYRAZOLES; PYRIDONES; RISK FACTORS; RIVAROXABAN; SALIVA, ARTIFICIAL; STROKE; VITAMIN K; WARFARIN;

EID: 85043682389     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.117.018395     Document Type: Article

References (36)

1. Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016;388:806-817. doi: 10.1016/S0140-6736(16)31257-0.
2. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet. 2014;383:955-962. doi: 10.1016/S0140-6736(13)62343-0.
3. Potpara TS, Lip GY. Postapproval observational studies of nonvitamin K antagonist oral anticoagulants in atrial fibrillation. JAMA. 2017;317:1115-1116. doi: 10.1001/jama.2017.1152.
4. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in realworld atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost. 2016;116:754-763. doi: 10.1160/TH16-03-0203.
5. Bai Y, Deng H, Shantsila A, Lip GY. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke. 2017;48:970-976. doi: 10.1161/STROKEAHA.116.016275.
6. Viswanathan M, Ansari M, Berkman N, Chang S, Hartling L, McPheeters L, et al. Methods guide for comparative effectiveness reviews assessing the risk of bias of individual studies in systematic reviews of health care interventions. www.effectivehealthcare.ahrq. gov/. Accessed April 2017.
7. Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2017. doi: 10.1093/europace/euw416.
8. Lee SI, Sayers M, Lip GY, Lane DA. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Int J Clin Pract. 2015;69:1341-1348. doi: 10.1111/ijcp.12712.
9. Shiga T, Naganuma M, Nagao T, Maruyama K, Suzuki A, Murasaki K, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: a single-center observational study. J Arrhythm. 2015;31:339-344. doi: 10.1016/j.joa.2015.04.004.
10. Al-Khalili F, Lindström C, Benson L. The safety and persistence of nonvitamin- K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Curr Med Res Opin. 2016;32:779-785. doi: 10.1185/03007995.2016.1142432.
11. Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016;32:2047-2053. doi: 10.1080/03007995.2016.1237937.
12. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
13. Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016;116:975-986. doi: 10.1160/TH16-05-0403.
14. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016;150:1302-1312. doi: 10.1016/j.chest.2016.07.013.
15. Staerk L, Fosbøl EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J. 2017;38:907-915. doi: 10.1093/eurheartj/ehw496.
16. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J. Am. Heart Assoc. 2016;5:e003725.
17. Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large populationbased study. Gastroenterology. 2017;152:1014-1022.e1. doi: 10.1053/j. gastro.2016.12.018.
18. Altay S, Yildirimtürk Ö, Çakmak HA, Askin L, Sinan Y, Besli F, et al; NOAC-TURK Study Collaborators. New oral anticoagulants-TURKey (NOAC-TURK): multicenter cross-sectional study. Anatol J Cardiol. 2017;17:353-361. doi: 10.14744/AnatolJCardiol.2016.7472.
19. Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3:28-36. doi: 10.1093/ehjcvp/pvw031.
20. Lamberts M, Staerk L, Olesen JB, Fosbøl EL, Hansen ML, Harboe L, et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. J Am Heart Assoc. 2017;6:e004517.
21. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in nonvalvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76, 940 patients. Thromb Haemost. 2017;117:1072-1082. doi: 10.1160/TH17-01-0068.
22. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.
23. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992 doi: 10.1056/NEJMoa1107039.
24. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, et al; GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103:307-314. doi: 10.1136/heartjnl-2016-309832.
25. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al; GLORIA-AF Investigators. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol. 2017;69:777-785. doi: 10.1016/j.jacc.2016.11.061.
26. Gadsbøll K, Staerk L, Fosbøl EL, Sindet-Pedersen C, Gundlund A, Lip GYH, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38:899-906. doi: 10.1093/eurheartj/ehw658.
27. Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69:2475-2484. doi: 10.1016/j. jacc.2017.03.540.
28. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962. doi: 10.1093/eurheartj/ehw210.
29. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e531S-e575S.
30. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al; CCS Atrial Fibrillation Guidelines Committee. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30:1114-1130. doi: 10.1016/j. cjca.2014.08.001.
31. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al; ORBIT-AF Investigators and Patients. Off-label dosing of nonvitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68:2597-2604. doi: 10.1016/j.jacc.2016.09.966.
32. Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017;48:2142-2149. doi: 10.1161/STROKEAHA.117.017474.
33. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84-91. doi: 10.1161/CIRCOUTCOMES.108.796185.
34. Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117:209-218. doi: 10.1160/TH16-10-0757.
35. Potpara TS, Boriani G, Lip GYH. Evaluating adherence to non-vitamin- K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation. Curr Med Res Opin. 2017;33:1175-1177. doi: 10.1080/03007995.2017.1313210.
36. Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberté F, et al. Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban. Curr Med Res Opin. 2017;33:1033-1043. doi: 10.1080/03007995.2017.1297932.